HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature
- 242 Downloads
We report the case of an 81-year-old patient with a pleomorphic giant cell adenocarcinoma of the prostate. After diagnosis, he rapidly developed bone metastasis and died within 1 year. This variant of acinar adenocarcinoma is extremely rare and prognosis is poor. This entity has been included into the 2016 WHO classification. The principal differential diagnosis is urothelial carcinoma. To assess the prostatic origin, routine immunohistochemistry can be problematic. Loss of epitopes in this poorly differentiated entity can occur, such as loss of expression of PSA and p504s. We recently described a very sensitive and specific marker of prostate cancer, HOXB13, which once again has proven to be highly specific and sensitive. This is the first description of a pleomorphic giant cell prostate cancer expressing HOXB13.
KeywordsProstate cancer Pleomorphic Giant cell Adenocarcinoma HOXB13
Compliance with ethical standards
The authors have accepted principles of ethical and professional conduct.
No funding was received.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Moch H, Humphrey PA, Ulbright TM, Reuter V (2016) WHO classification of tumours of the urinary system and male genital organs. International Agency for Research on Cancer, LyonGoogle Scholar
- 4.Mai KT, Burns BF, Morash D (1996) Giant-cell carcinoma of the prostate. J Urol Pathol 5:167–174Google Scholar
- 7.Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, Grading Committee (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason Grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252PubMedGoogle Scholar
- 8.Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel DE (2016) Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition. Arch Pathol Lab Med 140(6):543–551CrossRefPubMedGoogle Scholar